. * * window.aa needs to exist and be usable by ANY module's script, * however early it runs - main-nav's script, for one, runs near * the top of

91探花

, well before the real search-insights.js * so the download * begins as early as before. Repeat calls share the same downloads, a * failed load is retried on the next call, and the versions / SRI * hashes live only here. * * Algolia Insights is unaffected: window.aa above is still created in * on every page and queues events until search-insights loads. * * window.loadAlgoliaLibs({ priority: 'high' }) (Oct 2026): used by the * /search page, where the first results wait on these libraries. Chrome * gives async scripts low priority, behind images and fonts; this asks * for high instead (fetchpriority). Only the first call for a library * sets its priority - later calls share that download. */ (function (win, doc) { var LIBS = [ { ready: function () { return !!win['algoliasearch/lite']; }, src: 'https://cdn.jsdelivr.net/npm/algoliasearch@5.52.1/dist/lite/builds/browser.umd.js', integrity: 'sha256-I2oYUIvhx1g6l4lTP+yoERbzLIHKzw4AKaBRQPwIeDY=' }, { ready: function () { return !!win.instantsearch; }, src: 'https://cdn.jsdelivr.net/npm/instantsearch.js@4.98.0/dist/instantsearch.production.min.js', integrity: 'sha256-ngmqZk4WBxUw257aMYZayyNBd983INngagv0jI6Ecfs=' } ]; function loadOne(lib, options) { if (lib.ready()) return Promise.resolve(); // One download per library, shared by every caller; reset on // failure so the next call retries just the library that failed. if (lib.pending) return lib.pending; lib.pending = new Promise(function (resolve, reject) { var script = doc.createElement('script'); script.src = lib.src; script.integrity = lib.integrity; script.crossOrigin = 'anonymous'; script.async = true; if (options && options.priority === 'high') script.setAttribute('fetchpriority', 'high'); script.onload = function () { lib.ready() ? resolve() : reject(new Error('Loaded but not available: ' + lib.src)); }; script.onerror = function () { script.remove(); reject(new Error('Could not load ' + lib.src)); }; doc.head.appendChild(script); }); lib.pending.catch(function () { lib.pending = null; }); return lib.pending; } win.loadAlgoliaLibs = function (options) { return Promise.all(LIBS.map(function (lib) { return loadOne(lib, options); })); }; })(window, document); . */ window.hsConversationsSettings = window.hsConversationsSettings || {}; window.hsConversationsSettings.loadImmediately = false; (function (win) { var EVENTS = ['pointerdown', 'keydown', 'touchstart', 'scroll', 'mousemove', 'wheel']; var done = false; /* 19 Oct 2026 - chat widget layout shift (field CLS). Phones fail Core Web Vitals on CLS (p75 ~0.2 site-wide in CrUX for months). Biggest cause found: HubSpot's chat container is fixed to the bottom-right corner and changes size - 100x96 launcher to 282x253 when the welcome message pops up (~5 s after load), and to full screen when a visitor opens the chat. Its top-left corner moves, so Chrome scores it as a layout shift: 0.088 per page view at 360x640 (0.044 at 412x850), on every page. Taps happen inside the chat iframe, so the parent page never sees the input and the open/close shifts count too. Fix: whenever the container's size changes it is made transparent for 400 ms (Chrome doesn't score shifts of invisible elements), then shown again at its new size. Tested on live io1001 at 360x640 in a cookie-less frame: the 0.088 shift no longer appears. The chat itself is unchanged - it just appears 0.4 s later at each resize. Relies on HubSpot's container id; if that changes this does nothing (no error). */ function cloakChatResizes() { var ID = 'hubspot-messages-iframe-container'; function watch(c) { if (c.getAttribute('data-bb-cloak')) return; c.setAttribute('data-bb-cloak', '1'); var last = c.offsetWidth + 'x' + c.offsetHeight, timer = null; new MutationObserver(function () { var size = c.offsetWidth + 'x' + c.offsetHeight; if (size === last) return; last = size; c.style.setProperty('opacity', '0', 'important'); clearTimeout(timer); timer = setTimeout(function () { c.style.removeProperty('opacity'); }, 400); }).observe(c, { attributes: true, attributeFilter: ['style', 'class'], subtree: true, childList: true }); } var found = document.getElementById(ID); if (found) { watch(found); return; } if (!document.body || !('MutationObserver' in win)) return; var mo = new MutationObserver(function () { var c = document.getElementById(ID); if (c) { mo.disconnect(); watch(c); } }); mo.observe(document.body, { childList: true }); setTimeout(function () { mo.disconnect(); }, 30000); } function loadWidget() { var api = win.HubSpotConversations; if (api && api.widget && api.widget.status && api.widget.status().loaded) return; try { cloakChatResizes(); } catch (e) {} if (api && api.widget) api.widget.load(); } function onFirstInteraction() { if (done) return; done = true; EVENTS.forEach(function (type) { win.removeEventListener(type, onFirstInteraction, { passive: true }); }); var start = function () { if (win.HubSpotConversations) loadWidget(); else (win.hsConversationsOnReady = win.hsConversationsOnReady || []).push(loadWidget); }; if ('requestIdleCallback' in win) win.requestIdleCallback(start, { timeout: 1500 }); else setTimeout(start, 200); } EVENTS.forEach(function (type) { win.addEventListener(type, onFirstInteraction, { passive: true }); }); })(window);

91探花

Skip to main content
Home
About us
News
Charles River announces Bit Bio partnership, increasing drug discovery technologies

11.12.2019 | Published by Business Wire

Charles River announces Bit Bio partnership, increasing drug discovery technologies

Featured Image

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an exclusive Discovery and Safety Services partnership with Bit Bio, a company that offers consistent and efficient reprogramming of human cells for use in research, drug discovery, and cell therapies.

By applying an engineering approach to synthetic and stem cell biology, Bit Bio has developed proprietary technologies for the efficient, consistent, and scalable reprogramming of induced pluripotent stem cells.

Cellular Reprogramming

Cellular reprogramming is the process by which human stem cells, given a precise set of genetic instructions, differentiate into a desired cell type. Current cellular reprogramming approaches are inefficient, with low cell yields, creating a gap for applications requiring high quality, consistent, and pure human cells.

To overcome this hurdle, Bit Bio has developed a gene engineering approach, opti-ox (optimised inducible over-expression). This platform, validated on both muscle and brain cells, enables precise, controllable stem cell reprogramming. According to Bit Bio, the process is more efficient and scalable than available technologies in transforming stem cells into desired cell types.

By combining the purity, scale, and speed of the opti-ox platform with deep learning algorithms, Bit Bio has the potential to accelerate the discovery and application of every single human cell type.

Partnering for Translational Drug Development

By partnering with Bit Bio, Charles River plans to offer clients access to an expanding suite of authentic human cells through their use in target discovery, validation and screening services. In drug discovery and safety, the use of high quality, authentic human cells at scale will enable the development of therapies with a higher chance of success in patients. Additionally, through the partnership, Charles River will contribute to the development and validation of novel cell lines.

Approved Quotes

  • 鈥淏it Bio鈥檚 unique method of reprogramming human stem cells will have a significant impact on our ability to ensure we are discovering and developing therapies that are effective and safe in patients. We are excited to offer this next-generation technology as part of our comprehensive portfolio of drug discovery and development tools.鈥� 鈥� Birgit Girshick, Corporate Executive Vice President, Discovery and Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services at Charles River.
  • 鈥淲e believe that the next generation of medicine hinges on widespread access to human cells,鈥� said Bit Bio鈥檚 Chief Business Officer, Paul Morrill, PhD. 鈥淲e are excited to be partnering with Charles River Laboratories, a leader in drug development, to put our cells within a context to drive human translational experiments at the earliest stages of drug discovery and safety assessment.鈥�

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit .

View source version on businesswire.com:  

Source: Charles River Laboratories International, Inc.

Investor Contact:
Todd Spencer
Corporate Vice President, Investor Relations
781-222-6455
todd.spencer@crl.com 

Media Contacts:
Amy Cianciaruso
Corporate Vice President, Public Relations
781-222-6168
amy.cianciaruso@crl.com 

Related pages

About us Coding cells to advance the wellbeing of humanity
Careers See the latest openings
Blog See the latest blogs